US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. December 02, 2019

    Pfizer Claims No Link To Generic-Drug Price-Fix Plot

    Pfizer Inc. is seeking to exit the sweeping Pennsylvania multidistrict litigation alleging it conspired with other major drugmakers to keep generic prices high, as the branded drugmaker said its only ties to the allegations stem from a subsidiary, and that's not enough.

  2. December 02, 2019

    AGs Used Privileged Doc Again In Price-Fix Case: Pharma Co.

    Heritage Pharmaceuticals has told a Pennsylvania federal court that a group of states and territories led by Connecticut included a privileged email in the latest complaint filed in the sprawling generic-drug price-fixing litigation, even after the company tried to claw the document back.

  3. October 08, 2019

    Attys Denied Fee Set-Aside In Generics Antitrust Case

    Lawyers for two sets of litigants suing generic-drug makers in a price-fixing class action can't get a 10% set-aside from any future damages that parties taking their own direct actions ultimately win, a Pennsylvania federal judge has ruled, at least for now.

  4. September 16, 2019

    Generic Cos. Pan 'Irrelevant' Doc Demands In Price-Fix Case

    Numerous generic-drug makers entangled in a vast price-fixing suit in Pennsylvania federal court are slamming a special master's plan for discovery, claiming that his recommendation would force them to produce millions of documents the companies view as irrelevant.

  5. August 15, 2019

    Drugmakers Can't Ax MDL's 'Overarching Conspiracy' Claims

    A Pennsylvania federal judge refused on Thursday to throw out allegations in multidistrict litigation that Actavis, Teva, Mylan and other drugmakers engaged in a "broad overarching conspiracy" to fix generic-drug prices, saying the allegations are sufficiently pled and discovery is needed to determine if they're true.

  6. July 29, 2019

    Leaked Email In Price-Fixing Case Is Privileged, Heritage Says

    Heritage Pharmaceuticals told a Pennsylvania federal court Friday that an email it turned over to Connecticut's attorney general that was later used in the sprawling generic drug price-fixing litigation is privileged and should have been treated as confidential.

  7. July 22, 2019

    Conn. Denies Leaking Heritage Doc In Generic-Drug Case

    Connecticut's attorney general, one of several state AGs suing generic-drug companies alleging that they fixed prices, is defending the decision to refer in the complaint to an email suggesting Heritage Pharmaceuticals and other firms tried to obstruct a congressional probe into the generic-drug industry.

  8. July 10, 2019

    Heritage Says Conn. Leaked Email About Congressional Probe

    Heritage Pharmaceuticals accused Connecticut's attorney general on Tuesday of including a privileged email in a new generic-drug price-fixing complaint that suggests the company tried to obstruct a congressional investigation.

  9. June 26, 2019

    McKesson Dodges Generic Drug Price-Fix MDL For Now

    A Pennsylvania federal judge nixed claims Wednesday that McKesson Corp. earned billions of dollars by cooperating with an industry-wide price-fixing conspiracy among generic-drug makers, ruling that a putative class' allegations in the multidistrict litigation are impermissible suppositions.

  10. June 25, 2019

    Big Pharma's Biggest New Cases Of 2019: Midyear Report

    Multibillion-dollar lawsuits targeting major drugmakers emerged with astonishing frequency during the first half of 2019, threatening civil and criminal liability for all manner of alleged wheeling and dealing. Here, Law360 highlights the latest developments and upcoming action in the pharmaceutical world's hottest new cases.